| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 06/02/2000 | WO2000030578A1 Enzymatic treatment and prevention of hypertrophic skin |
| 06/02/2000 | WO2000014236A3 Grf analogs with increased biological potency |
| 06/02/2000 | WO2000013710A3 Hydrogel compositions for the controlled release administration of growth factors |
| 06/02/2000 | WO2000012119A3 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa |
| 06/02/2000 | CA2352665A1 Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof |
| 06/02/2000 | CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | CA2352477A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof |
| 06/02/2000 | CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 06/02/2000 | CA2352144A1 Scavenger compounds |
| 06/02/2000 | CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists |
| 06/02/2000 | CA2351718A1 Desmethylolanzapine compositions and methods |
| 06/02/2000 | CA2351631A1 Piperidine quaternary salts-ccr-3 receptor antagonists |
| 06/02/2000 | CA2351630A1 Vector |
| 06/02/2000 | CA2351361A1 Gtpase associated proteins |
| 06/02/2000 | CA2349721A1 N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases |
| 05/31/2000 | EP1004315A1 Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient |
| 05/31/2000 | EP1003857A2 Secreted proteins and polynucleotides encoding them |
| 05/31/2000 | EP1003770A1 Secreted proteins and polynucleotides encoding them |
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003748A2 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase |
| 05/31/2000 | EP1003745A1 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation |
| 05/31/2000 | EP1003729A1 6-azauracil derivatives as il-5 inhibitors |
| 05/31/2000 | EP1003723A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 05/31/2000 | EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases |
| 05/31/2000 | EP1003577A1 Blood product delivery system |
| 05/31/2000 | EP1003559A2 Immobilization of vitamin a acid by cationic polyelectrolytes |
| 05/31/2000 | EP1003545A1 Heparin-binding growth factor (hbgf) polypeptides |
| 05/31/2000 | EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 05/31/2000 | EP1003538A1 Use of polygonatum extracts for stimulating dermal elastin synthesis |
| 05/31/2000 | EP1003537A1 Et |
| 05/31/2000 | EP1003526A1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 05/31/2000 | EP1003509A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003504A2 Indole derivatives and their use as mcp-1 antagonists |
| 05/31/2000 | EP1003502A1 Enantiomers of 4- (cyanoimino)- (1,2,2-trimethylpropyl) amino]methyl]amino] benzonitrile |
| 05/31/2000 | EP1003497A1 Il-8 receptor antagonists |
| 05/31/2000 | EP1003493A1 Use of selective rxr agonists to prevent surgical adhesions |
| 05/31/2000 | EP1003489A1 Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith |
| 05/31/2000 | EP1003479A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases |
| 05/31/2000 | EP1003473A1 Composition and method for treatment of aging skin |
| 05/31/2000 | EP0865428B1 Vitamin d analogues |
| 05/31/2000 | EP0794942B1 Substituted biphenyl compounds for the treatment of inflammation |
| 05/31/2000 | DE19955340A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists |
| 05/31/2000 | DE19856475A1 Nichtsteroidale Entzündungshemmer Nonsteroidal anti-inflammatory drugs |
| 05/31/2000 | CN1255053A Ascorbyl-phosphoryl-cholesterol |
| 05/31/2000 | CN1254593A Cleaning liquid for treating tinear and its preparing process |
| 05/31/2000 | CN1254590A Medicinal liquor |
| 05/31/2000 | CN1254562A Process for preparing exterior-applied medicine for treating psoriasis |
| 05/31/2000 | CN1052914C Medicinal pill for curing leucodema |
| 05/31/2000 | CN1052907C Chinese herbal medicine for treating burn, skin and external diseases and preparing process thereof |
| 05/31/2000 | CN1052901C Traditional Chinese medicine pill for treating psoriasis and its producing method |
| 05/31/2000 | CN1052898C Brightening and spot-removing face-beautifying preparation and its preparation method |
| 05/31/2000 | CN1052884C Traditional Chinese medicine Baiyuwan pill for treating vitiligo |
| 05/31/2000 | CN1052883C Traditional Chinese medicine kexuanwan pill for treating psoriasis |
| 05/31/2000 | CN1052881C 烧、烫伤软膏 Burn, burn ointment |
| 05/30/2000 | US6069169 Dermatologic and cosmetic use for oxa acids |
| 05/30/2000 | US6069150 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents |
| 05/30/2000 | US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| 05/30/2000 | US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences |
| 05/30/2000 | US6068860 For topical administration comprising foscarnet and an antiinflammatory glucocorticoid, with a carrier based on galactolipids comprising digalactosyldiacylglycerols, and a polar solvent; treating herpes infections |
| 05/30/2000 | US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV |
| 05/30/2000 | US6068845 Inhibitory activity on the abnormal production of extracellular matrices in dermal fibroblasts activated with tranforming growth factor beta by administering the plant extract of a plant belonging to the genus sophora |
| 05/30/2000 | CA2083333C High dosage topical forms of collagenase |
| 05/25/2000 | WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029447A1 Rhamm antagonist antibodies |
| 05/25/2000 | WO2000029438A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | WO2000029435A1 12 human secreted proteins |
| 05/25/2000 | WO2000029425A1 Physiologically active peptides |
| 05/25/2000 | WO2000029422A1 31 human secreted proteins |
| 05/25/2000 | WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | WO2000029377A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 05/25/2000 | WO2000028988A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000028975A2 Improved chemical process and pharmaceutical formulation |
| 05/25/2000 | WO2000028971A1 Nano-emulsion of 5-aminolevulinic acid |
| 05/25/2000 | WO2000028947A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | WO2000028928A1 Compositions expressing a pressure of carbon dioxide for improved healing of wounds |
| 05/25/2000 | WO2000028821A1 Therapeutic anti-fungal nail preparation |
| 05/25/2000 | WO2000018428A3 Hedgehog and patched antagonists for inhibiting cell and tissue growth and differentiation and uses therefor |
| 05/25/2000 | WO2000018361A3 Method of treating hair loss using sulfonamides |
| 05/25/2000 | WO2000012111A3 Selective treatment of endothelial somatostatin receptors |
| 05/25/2000 | WO2000012049A3 A method for the treatment of staphylococcal disease |
| 05/25/2000 | WO1999053949A9 Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy |
| 05/25/2000 | DE19955793A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists |
| 05/25/2000 | DE19937794A1 Composition useful for promoting wound healing comprises eugenol and polyphenols |
| 05/25/2000 | DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| 05/25/2000 | CA2351522A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350722A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2349919A1 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | CA2349575A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/25/2000 | CA2347833A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 05/24/2000 | EP1002802A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1002799A1 Optically pure androgen mediator |
| 05/24/2000 | EP1002536A2 2-Amino, 4-alkylamino pyrimidine 3-oxydes as soothing agents for the skin |